%0 Journal Article
%A Shahswar, Rabia
%A Beutel, Gernot
%A Gabdoulline, Razif
%A Schwarzer, Adrian
%A Kloos, Arnold
%A Koenecke, Christian
%A Stadler, Michael
%A Gohring, Gudrun
%A Behrens, Yvonne Lisa
%A Li, Zhixiong
%A Dallmann, Louisa-Kristin
%A Klement, Piroska
%A Albert, Catherin
%A Wichmann, Martin
%A Alwie, Yasmine
%A Benner, Axel
%A Saadati, Maral
%A Ganser, Arnold
%A Thol, Felicitas
%A Heuser, Michael
%T Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.
%J Haematologica
%V 109
%N 1
%@ 0390-6078
%C Pavia
%I Ferrata Storti Foundation
%M DKFZ-2023-01475
%P 72-83
%D 2024
%Z 2024 Jan 1;109(1):72-83
%X Treatment options for relapsed and refractory acute myeloid leukemia patients (R/R AML) are limited. This retrospective cohort study compares safety and efficacy of fludarabine, cytarabine, and idarubicin (FLA-IDA) with or without venetoclax in patients with R/R AML. Thirty-seven and 81 patients received one course FLA-IDA with or without a 7-day course of venetoclax, respectively. The overall response rate (ORR) was significantly higher in FLAVIDA compared to FLA-IDA treated patients (78
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37470150
%R 10.3324/haematol.2023.282912
%U https://inrepo02.dkfz.de/record/277758